Matching articles for "Uzedy"
Issue 1746 · January 19, 2026 Free
In Brief: A New Indication for Uzedy

Uzedy , an extended-release, subcutaneous (SC) formulation of the second-generation antipsychotic drug risperidone, was approved by the FDA in 2023 for treatment of schizophrenia in adults. It has now been…

Med Lett Drugs Ther. 2026 Jan 19; 68(1746):15-6 doi:10.58347/tml.2026.1746e
Uzedy , an extended-release, subcutaneous (SC) formulation of the second-generation antipsychotic drug risperidone, was approved by the FDA in 2023 for treatment of schizophrenia in adults. It has now been approved for use as monotherapy or in combination with lithium or valproate for maintenance treatment of bipolar I disorder in adults. Extended-release, intramuscular (IM) formulations of risperidone ( Risperdal Consta and Rykindo ) are also approved for treatment of bipolar I disorder (see Table 1).
Issue 1692 · December 25, 2023 Free
In Brief: Three New Injectable Antipsychotic Drugs

Three extended-release injectable formulations of second-generation antipsychotic drugs — two of risperidone (Rykindo, Uzedy) and one of aripiprazole (Abilify Asimtufii) — have been approved by the FDA for…

Med Lett Drugs Ther. 2023 Dec 25; 65(1692):207-8 doi:10.58347/tml.2023.1692d
Three extended-release injectable formulations of second-generation antipsychotic drugs — two of risperidone (Rykindo, Uzedy) and one of aripiprazole (Abilify Asimtufii) — have been approved by the FDA for treatment of schizophrenia in adults. Rykindo and Abilify Asimtufii are also approved for maintenance treatment of bipolar I disorder in adults. Other extended-release injectable formulations of risperidone and aripiprazole have been available in the US for years (see Table 1).